Robert Teachenor

Robert Teachenor is a highly experienced scientist and lab manager with expertise in molecular biology and genetics. Currently serving as a Scientist/Lab Manager at Overland Pharmaceuticals since March 2023, Robert specializes in developing Chimeric Antigen Receptor T (CAR-T) cell lines. Prior roles include significant positions at Scribe Therapeutics, where over 200 CRISPR-associated molecules were screened for genetic editing capabilities, and Bristol-Myers Squibb, focusing on IL-2 mutein candidates for auto-immune disease treatment. Robert's extensive background includes research at Genentech, UNITY Biotechnology, and One Lambda, Inc., as well as academic experience from UC San Diego and Berkeley, culminating in a PhD in Molecular Biology.